Mevacor OTC Study Shows High-Risk Users Will “Upstream,” Merck Says

Merck's educational strategy for potential over-the counter sale of 20 mg Mevacor (lovastatin) will prevent rather than increase undertreatment among people who should be using more aggressive statin therapy, the firm contends

More from Archive

More from Pink Sheet